Please use this identifier to cite or link to this item:
|Title:||Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group|
Hepatitis B virus
|Citation:||Kim, S.J., Hsu, C., Song, Y.-Q., Tay, K., Hong, X.-N., Cao, J., Kim, J.S., Eom, H.S., Lee, J.H., Zhu, J., Chang, K.-M., Reksodiputro, A.H., Tan, D., Goh, Y.T., Lee, J., Intragumtornchai, T., Chng, W.-J., Cheng, A.-L., Lim, S.T., Suh, C., Kwong, Y.-L., Kim, W.S. (2013-11). Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. European Journal of Cancer 49 (16) : 3486-3496. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ejca.2013.07.006|
|Abstract:||Background Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used for B-cell lymphoma. Thus, prevention and management of HBV reactivation are important in HBV-endemic areas. Methods Hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)-positive patients and HBsAg-negative/HBV core antibody (HBcAb)-positive patients who received rituximab-containing chemotherapy was investigated by the Asia Lymphoma Study Group via retrospective (n = 340), and the results were compared to cross-sectional analysis with patients who were prospectively monitored in a single institute (n = 127). The goal of the study was to define the frequency of HBV reactivation and the efficacy of antiviral prophylaxis. Results HBV reactivation was found in 27.8% of HBsAg-positive patients (45/162) in the retrospective analysis, being significantly less frequent in patients receiving antiviral prophylaxis than those not (22.9%, 32/140 versus 59.1%, 13/22; p < 0.001). Lamivudine was most commonly used (96/162, 59.3%), but more than 20% of HBsAg-positive patients showed breakthrough HBV reactivation. In the cross-sectional analysis, a reduced rate of HBV reactivation occurred for entecavir as compared with lamivudine prophylaxis (6.3% versus 39.3%; p < 0.05). HBV DNA monitoring of HBsAg-negative/HBcAb-positive patients in the cross-sectional analysis showed HBV reactivation in only 2.4% of cases. Conclusions This is the largest study of HBV reactivation in patients receiving rituximab-containing chemotherapy to date, and we defined the probability of HBV reactivation in an HBV-endemic region. © 2013 Elsevier Ltd. All rights reserved.|
|Source Title:||European Journal of Cancer|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 16, 2018
WEB OF SCIENCETM
checked on May 30, 2018
checked on Jun 14, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.